Shareholders may find more information at https://securitiesclasslaw.com/securities/endo-international-plc-loss-submission-form/?id=7997&from=1 Chembio Diagnostics, Inc. ( CEMI ) Investors Affected: March 12, 2020 - June 16, 2020 A class action has commenced on behalf of certain shareholders in Chembio Diagnostics, Inc. According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test.